Table 5 Characteristics of patients... | American Society of Hematology

Table 5

Characteristics of patients responding to MGCD0103

	Patient number
	1	2	3
Age, y	76	52	58
Sex	Male	Female	Male
Disease	MDS; INT-1	AML	AML
Cytogenetics	Diploid	Complex, 43-46, X, −X, add (3) (q35), +10, t(11;12) (p13;p12)	Diploid
Prior treatment	None	Ida + Ara-C; high-dose Ara-C	Decitabine; Ida + Ara-C; Fludara + Ara-C
Treatment course	80 to 60 mg/m²	80 to 60 mg/m²	60 mg/m²
Time to response	2 cycles	2 cycles	1 cycle
Response duration	No repeat aspirate	3 cycles	1 cycle
On study duration	4 cycles	5 cycles	4 cycles
Max HDAC inhibition, %*	23	63	38
Max histone acetylation, %*	149	337	338

	Patient number
	1	2	3
Age, y	76	52	58
Sex	Male	Female	Male
Disease	MDS; INT-1	AML	AML
Cytogenetics	Diploid	Complex, 43-46, X, −X, add (3) (q35), +10, t(11;12) (p13;p12)	Diploid
Prior treatment	None	Ida + Ara-C; high-dose Ara-C	Decitabine; Ida + Ara-C; Fludara + Ara-C
Treatment course	80 to 60 mg/m²	80 to 60 mg/m²	60 mg/m²
Time to response	2 cycles	2 cycles	1 cycle
Response duration	No repeat aspirate	3 cycles	1 cycle
On study duration	4 cycles	5 cycles	4 cycles
Max HDAC inhibition, %*	23	63	38
Max histone acetylation, %*	149	337	338

Inhibition of HDAC activity and histone acetylation were measured in peripheral white cells collected from the patients (“Histone acetylation”).